Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic characteristics and drug screening among organoids derived from non‐small cell lung cancer patients

7 Jul 2020

Abstract excerpt

BACKGROUND: Patient-derived organoid (PDO) models are highly valuable and have potentially widespread clinical applications. However, limited information is available regarding organoid models of non-small cell lung cancer (NSCLC). This study aimed to characterize the consistency between primary tumors in NSCLC and PDOs and to explore the applications of PDOs as preclinical models to understand and predict...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer Genomics and Diagnostics
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32633046
DOI: 10.1111/1759-7714.13542

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic characteristics and drug screening among organoids derived from non‐small cell lung cancer patientsPMID 32633046Read ↗

Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Human Lung Adenocarcinoma-Derived Organoid Models for Drug ScreeningSemantic proximity Read ↗

Patient-derived tumor organoids from resected non-small cell lung cancers for high-throughput response testing with approved and repurposed drugsSemantic proximity Read ↗

<em>Ex Vivo</em> Drug Testing of Patient-Derived Lung Organoids to Predict Treatment Responses for Personalized MedicineSemantic proximity Read ↗

Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screeningSemantic proximity Read ↗

An optimized method to culture human primary lung tumor cell spheroidsSemantic proximity Read ↗

Patient-derived organoids from malignant pleural effusion to explore for alternative therapies in thoracic tumorsSemantic proximity Read ↗

Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a weekSemantic proximity Read ↗

Establishment, characterization, and drug screening of low-passage patient individual non-small cell lung cancer in vitro models including the rare pleomorphic subentitySemantic proximity Read ↗

Utility of patient-derived xenografts to evaluate drug sensitivity and select optimal treatments for individual non-small-cell lung cancer patientsSemantic proximity Read ↗

Lung tumoroids as a testing platform for precision CAR T-cell therapySemantic proximity Read ↗

A novel artificial lung organoid for simulating a patient derived adenocarcinoma of lung for personalized oncologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.